Andrea Biondi

Full Professor

University of Milano-Bicocca

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Andrea Biondi is a Full Professor at the University of Milano-Bicocca in Italy. His research primarily focuses on pediatric hematology and oncology, addressing topics such as the treatment of acute lymphoblastic leukemia and stem cell transplantation methodologies. Recent articles reflect his interest in the risk factors for eating disorders in adolescents with inflammatory bowel diseases, as well as the management of iron overload in post-transplant patients. He is actively involved in advancing clinical practices and therapeutic strategies in the field.

Articles (13)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (7)

MARTA SERAFINI

Adjunct Professor

University of Milano-Bicocca

ITALY

View details

Jan Zuna

Charles University

CZECH REPUBLIC

View details

Adriana Balduzzi

ITALY

View details

PAOLA VAGO

assistant professor

Università Cattolica del Sacro Cuore

ITALY

View details

Giovanni Cazzaniga

Associate Professor

University of Milano-Bicocca

ITALY

View details

Saverio Tardito

University of Glasgow

UNITED KINGDOM

View details

Claus Meyer

Head of DCAL, PhD

Goethe University Frankfurt

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrea Biondi

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Risk Factors for the Development of Eating Disorders in Adolescents with Early-Onset Inflammatory Bowel Diseases

ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?

Is There a Pediatric Role for the General Thoracic Surgeon in a General Hospital? A 22-Year Single-Center Experience

A Hematopoietic Stem Cell Transplantation Startup in Iraqi Kurdistan: Results in Thalassemia Patients and Analysis of the Methodology

Iron Overload Following Hematopoietic Stem Cell Transplantation: Prevalence, Severity, and Management in Children and Adolescents with Malignant and Nonmalignant Diseases

A primarily clinician's responsibility

Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium

The Impact of a Precision-Based Exercise Intervention in Childhood Hematological Malignancies Evaluated by an Adapted Yo-Yo Intermittent Recovery Test

Catch me if you can: how AML and its niche escape immunotherapy

Evidence of Treatment Benefits in Patients with Mucopolysaccharidosis Type I-Hurler in Long-term Follow-up Using a New Magnetic Resonance Imaging Scoring System

Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment

Collaborators (7)

MARTA SERAFINI

Jan Zuna

Adriana Balduzzi

PAOLA VAGO

Giovanni Cazzaniga

Saverio Tardito

Claus Meyer

Make your next move.